Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Eton Pharmaceuticals (ETON) Revenue (2019 - 2025)

Eton Pharmaceuticals (ETON) has disclosed Revenue for 7 consecutive years, with $21.3 million as the latest value for Q4 2025.

  • Quarterly Revenue rose 82.72% to $21.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $64.5 million through Dec 2025, up 65.22% year-over-year, with the annual reading at $80.0 million for FY2025, 104.94% up from the prior year.
  • Revenue hit $21.3 million in Q4 2025 for Eton Pharmaceuticals, down from $22.5 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $29.8 million in Q4 2023 to a low of $775000.0 in Q3 2021.
  • Historically, Revenue has averaged $9.9 million across 5 years, with a median of $8.2 million in 2022.
  • Biggest five-year swings in Revenue: soared 203200.0% in 2021 and later crashed 81.71% in 2022.
  • Year by year, Revenue stood at $6.1 million in 2021, then soared by 39.47% to $8.5 million in 2022, then surged by 250.69% to $29.8 million in 2023, then crashed by 60.92% to $11.6 million in 2024, then skyrocketed by 82.72% to $21.3 million in 2025.
  • Business Quant data shows Revenue for ETON at $21.3 million in Q4 2025, $22.5 million in Q3 2025, and $18.9 million in Q2 2025.